Zentalis Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZNTL research report →
Companyzentalis.com
Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- CEO
- Julie Eastland
- IPO
- 2020
- Employees
- 166
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $262.84M
- P/E
- -2.09
- P/S
- 0.00
- P/B
- 1.42
- EV/EBITDA
- -1.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.61%
- ROIC
- -66.58%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-137,060,000 · 17.35%
- EPS
- $-1.91 · 18.03%
- Op Income
- $-152,808,000
- FCF YoY
- 26.79%
Performance & Tape
- 52W High
- $6.95
- 52W Low
- $1.13
- 50D MA
- $3.61
- 200D MA
- $2.27
- Beta
- 2.00
- Avg Volume
- 2.02M
Get TickerSpark's AI analysis on ZNTL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 6, 26 | Bruns Ingmar | sell | 2,962 |
| Feb 9, 26 | Bruns Ingmar | sell | 335 |
| Feb 6, 26 | Vultaggio Vincent | sell | 29,951 |
| Feb 9, 26 | Vultaggio Vincent | sell | 3,379 |
| Feb 10, 26 | Vultaggio Vincent | sell | 6,894 |
| Feb 6, 26 | EASTLAND JULIA MARIE | sell | 7,866 |
| Feb 9, 26 | EASTLAND JULIA MARIE | sell | 889 |
| Feb 2, 26 | Vultaggio Vincent | sell | 2,540 |
| Feb 3, 26 | Vultaggio Vincent | sell | 556 |
| Jan 8, 26 | Vultaggio Vincent | other | 100,000 |
Our ZNTL Coverage
We haven't published any research on ZNTL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZNTL Report →